Speakers - Sachs Associates

Speakers
Carlos Paya, CEO, Immune Design Corp.
Carlos joined Immune Design Corp. in May 2011 as President and Chief Executive Officer. He previously served as President
of Elan Corporation and led the biotechnology company’s commercial, marketing, clinical, research, and development teams
from 2008 to 2011. Before joining Elan, Dr. Paya was at Eli Lilly & Company as Vice President, Lilly Research Laboratories
where he led various therapeutic areas encompassing discovery, clinical development, and the Diabetes and Endocrine
franchise. Prior to this, Dr. Paya was Professor of Medicine, Immunology, and Pathology, and Vice Dean of the Clinical
Investigation Program at the Mayo Clinic in Rochester, Minnesota. He received his MD and PhD degrees from the University
of Madrid and underwent postdoctoral training at the Institute Pasteur, Paris, France.
Carole Nuechterlein, VP Corporate Licensing, Takeda Pharmaceuticals International GmbH
Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the
pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont California where
she was General Counsel.
Carole began her career working at Skadden Arps Slate Meagher & Flom in the M&A group. From there, she worked at
Syntex/Roche in Palo Alto, California focusing on M&A, research collaborations and licensing deals. Due to her background in
M&A, Carole led the negotiation team for the Roche acquisitions of GlycArt and Therapeutic Human Polyclonals.
She currently serves as a board observer at Aileron, Alios, Ambit, Ambrx, Conatus, Envoy, Idaho Technology and Nereus.
She has a BA from Valparaiso University and a JD from University of Michigan. More information on the Roche Venture Fund
can be found at www.venturefund.roche.com.
Catherine Pickering, Head of Oncology, Merck Serono
Specialties: Leading a team of BD professionals focussed in the oncology licensing field. Licesning of preclinical and clinical
stage products within biotechnology and pharmaceutical companies.
Technology Transfer within UK Oncology Research Institution for four years. Responsible for protecting and exploition the
Institution’s IP.
More recently business development role within Oncology company.
Chirs Britten, Independent Consultant
Chris has a scientific background, a PhD in biochemistry and an MBA. Chris has gained huge experience and contacts
in the Life Sciences market having negotiated a variety of acquisitions, licences, divestments and strategic alliances with
partners around the world.
Current activities include advising clients across the spectrum of the Life Science sector, from molecular diagnostics to
biotechnology, generics to specialty pharmaceuticals and OTC products.
Christof Boehler, CEO, Pantec Biosolutions
After finishing his PhD in chemistry at ETH Zurich dealing with bio-polymeric drug release systems, Dr. Christof Böhler moved
to the United States for a Postdoc at the Salk and Scripps Research Institutes in La Jolla (CA, USA) carrying out bio-medical
basic research.
From there he started to work as the head of development for a start up biotech company in Zurich, whose process has
now been commercialized. Realizing the need to develop his commercial know-how, he moved into product management of
research chemicals and biologicals at Fluka Chemie AG (a Sigma Aldrich company, Buchs, CH).
During his Fluka time he completed a postgraduate executive degree in “International Management” at the FH Liechtenstein
and UBC Vancouver (Canada). His further career involved Business Development Manager Europe and Business Manager
for Maybridge, a Drug Discovery service company, and finally Marketing Director “Drug Discovery Chemicals” for Acros/
Maybridge (Fisher Scientific).
t back :: next u
WELCOME PHARMA LICENSING GROUPS
SPEAKERS
PRESENTING COMPANIES SUPPORTING ORGANISATIONS
ORGANISERS